Allogeneic peripheral blood stem cell transplantation for active hemophagocytic lymphohistiocytosis

K. W. Chan, C. A. Mullen, M. Korbling

Research output: Contribution to journalArticle

7 Scopus citations


Hemophagocytic lymphohistiocytosis (HLH) is a lethal disorder of immune dysregulation. Successful allogeneic BMT is the only therapy that has produced long-term disease-free survival. However, for patients with active HLH the outcome of BMT remains poor when compared with those transplanted in remission. We describe a patient with active, recurrent HLH treated with highdose chemotherapy and related allogeneic peripheral blood stem cell (PBSC) transplantation. Hematologic recovery was rapid and the post-transplant course was uncomplicated. The patient is alive and well 2 1/4 years after transplant. Allogeneic PBSC transplantation may deserve further evaluation as an alternative source of stem cells for transplantation in patients with active HLH.

Original languageEnglish (US)
Pages (from-to)301-302
Number of pages2
JournalBone marrow transplantation
Issue number3
StatePublished - Jan 1 1998


  • Allogeneic
  • Hemophagocytic lymphohistiocytosis
  • Peripheral blood stem cell
  • Transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Allogeneic peripheral blood stem cell transplantation for active hemophagocytic lymphohistiocytosis'. Together they form a unique fingerprint.

  • Cite this